RBC Capital raised the firm’s price target on Cidara Therapeutics (CDTX) to $115 from $75 and keeps an Outperform rating on the shares. After having consulted with “a top antiviral expert” to get his reactions to Cidara’s recent NAVIGATE Phase IIb data, the firm came away “even more optimistic” on ‘388’s ultimate market potential, which the firm now sees as $3.3B in worldwide peak sales, the analyst tells investors. The firm is “increasingly convinced there remains a significant valuation disconnect and room for considerable additional fundamental upside,” the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics price target raised to $69 from $68 at Guggenheim
- Cidara Therapeutics announces inclusion in Russell 2000, 3000 Indexes
- Cidara Therapeutics Announces $350 Million Stock Offering
- Cidara Therapeutics 7.95M share Secondary priced at $44.00
- Cidara Therapeutics Suspends ATM Prospectus with Jefferies